Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ganglioside GD3 is a disialoganglioside involved in various cellular processes, including neurogenesis, apoptosis, and autophagy. It is overexpressed in several cancers, making it a potential target for immunotherapy. GD3 is synthesized from GM3 by GD3 synthase (ST8Sia I) and is found in high concentrations in developing brain tissue and some tumors.
GD3 serves as a target for cancer immunotherapy strategies due to its tumor-associated expression patterns. It modulates EGFR signaling and influences apoptosis and autophagy pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ganglioside GD3 (None).